Keros Therapeutics Inc
NASDAQGM:KROS
United States / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
11.55 USD
Day change
0.33 (2.90%)
52-week range
9.78 - 72.37
19:38 - Real Time Data
Summary of Keros Therapeutics Inc
Hide this widget
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that ...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| KROS | Peers | Sector | |
|---|---|---|---|
Market Cap | 455.1 M | 69.268 M | 66.257 M |
Price % of 52 Week High | 15.8% | 46.2% | 62.8% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -87.2% | -9.9% | -0.7% |
1 Year Price Total Return | -83.0% | -53.0% | -11.0% |
Beta (5 Year) | 1.40 | 1.11 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
14.98
Upside
29.7%
Uncertainty
HIGH
Spread
10.94 - 21.51
Market Range
52 weeks
$10
$72
$11.55
Analyst Targets
11 analysts
$15
$76
$33.64
Investing Models
$14.98
Financial Health
Health Details
Hide this widget
Financial Health for Keros is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Weak Performance
▼
▼
Financial Models for Keros Therapeutics Inc
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 1 day ago |
| Earnings Power ValueView Updated 22 hours ago |
| 10Y Historical FinancialsView Updated 1 day ago |
| 5Y Historical FinancialsView Updated 1 day ago |
| EV / EBIT MultiplesView Updated 22 hours ago |
| EV / EBITDA MultiplesView Updated 22 hours ago |
| P/E MultiplesView Updated 22 hours ago |
| Price / Book MultiplesView Updated 22 hours ago |
| Price / Sales MultiplesView Updated 22 hours ago |
| EV / Revenue MultiplesView Updated 22 hours ago |
| CAPM WACC ModelView Updated 2 hours ago |
| 10Y DCF EBITDA ExitView Updated 22 hours ago |
| 10Y DCF Revenue ExitView Updated 22 hours ago |
| 10Y DCF Growth ExitView Updated 22 hours ago |
| 5Y DCF EBITDA ExitView Updated 22 hours ago |
| 5Y DCF Revenue ExitView Updated 22 hours ago |
| 5Y DCF Growth ExitView Updated 22 hours ago |
Historical Financials
Full Financials
Hide this widget
| (USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 0.15 | 3.55 | 0.14 | 3.04 | |
| Operating Income | (115) | (170) | (211) | (46) | (53) |
| Net Profit | (105) | (153) | (187) | (40) | (46) |
| Diluted EPS | -4.15 | -5.20 | -5 | -1.34 | -1.14 |
| EBITDA | (114) | (169) | (210) | (46) | (53) |
| Balance Sheet | |||||
| Cash & ST Invest. | 279 | 331 | 560 | 331 | 560 |
| Current Assets | 286 | 347 | 589 | 347 | 589 |
| Total Assets | 307 | 370 | 616 | 370 | 616 |
| Current Liabilities | 17 | 24 | 27 | 24 | 27 |
| Total Liabilities | 29 | 38 | 44 | 38 | 44 |
| Total Equity | 277 | 332 | 572 | 332 | 572 |
| Total Debt | 13 | 14 | 19 | 14 | 19 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (70) | (125) | (161) | (25) | (46) |
| Cash From Investing | (1.24) | (2.46) | (1.93) | (0.54) | (0.29) |
| Cash From Financing | 120 | 179 | 392 | 69 | 76 |
| Free Cash Flow | (71) | (127) | (163) | (26) | (46) |
Analyst Notes
March 24, 2025
Hide this widget